• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

POLL: Which Recent FDA Update Was Most Exciting?

Poll

Click here to answer this week's poll.

Baricitinib FDA Approved to Treat Alopecia Areata
Dupilumab FDA Approved for AD Patients 6 months to 5 years
TMB-001 Granted FDA Breakthrough Therapy Designation
FDA Grants Priority Review for Dupilumab sBLA for Adults with Prurigo Nodularis
Tapinarof Cream 1% is FDA Approved
Related Videos
infectious disease
Related Content
MoonLake Immunotherapeutics and Komodo Health to Partner to Improve Research on Inflammatory Skin Conditions

MoonLake Immunotherapeutics and Komodo Health to Partner to Improve Research on Inflammatory Skin Conditions

Article
The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

Podcast
Pelthos Therapeutics Launches to Accelerate Commercialization of Treatment for Molluscum Contagiosum

Pelthos Therapeutics Launches to Accelerate Commercialization of Treatment for Molluscum Contagiosum

Article
The Cutaneous Connection

The Cutaneous Connection: Episode 30- Impact of the JAK Inhibitor Approval Delays

Podcast
Soligenix and European Medicines Agency Settle on Design of Second Placebo-Controlled Trial of HyBryte in CTCL

Soligenix and European Medicines Agency Settle on Design of Second Placebo-Controlled Trial of HyBryte in CTCL

Article
Recapping March Dermatology Biosimilar News

Recapping March Dermatology Biosimilar News

Article
© 2024 MJH Life Sciences

All rights reserved.